Literature DB >> 10570439

Expression of telomerase mRNA component (hTR) in transitional cell carcinoma of the upper urinary tract.

K Nakanishi1, T Kawai, S Hiroi, F Kumaki, C Torikata, T Aurues, T Ikeda.   

Abstract

BACKGROUND: Telomerase is a ribonucleoprotein enzyme that synthesizes telomeric repeats onto chromosomal ends using a segment of its RNA component as a template. Its activity has become an established indicator of the diagnosis, biologic behavior, and prognosis of several tumors. However, to the authors' knowledge, no previous study has investigated the diagnostic and prognostic importance of the expression of telomerase RNA component (hTR) in transitional cell carcinoma of the upper urinary tract (TCC-UUT).
METHODS: The authors investigated hTR expression using in situ hybridization in 130 cases of TCC-UUT, and also its relation to proliferating cell nuclear antigen (PCNA) immunoreactivity, immunoreactivity for p53 oncoprotein, clinicopathologic parameters, and clinical outcome.
RESULTS: Positive hTR expression was recognized in 98.4% of the samples and was apparent within the cytoplasm of tumor cells. In normal urothelium, its expression was restricted to the basal cell layers, whereas in the dysplastic lesions of TCC-UUT it was detected with the same intensity and distribution as in the tumor itself. No correlation was found between hTR expression and clinicopathologic findings, PCNA index, or the expression of p53 oncoprotein, although hTR score did tend to increase with disease stage. In univariate and multivariate analyses of disease free and overall survival rates, high hTR expression was associated with significant decreases in both rates.
CONCLUSIONS: The expression of hTR appears to be a useful indicator of prognosis for patients with TCC-UUT. In addition, evidence of up-regulation of hTR may also be useful in the diagnosis of this disease. Copyright 1999 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10570439

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Expression of steroid hormone receptors and its prognostic significance in urothelial carcinoma of the upper urinary tract.

Authors:  Eiji Kashiwagi; Kazutoshi Fujita; Seiji Yamaguchi; Hiroaki Fushimi; Hiroki Ide; Satoshi Inoue; Taichi Mizushima; Leonardo O Reis; Rajni Sharma; George J Netto; Norio Nonomura; Hiroshi Miyamoto
Journal:  Cancer Biol Ther       Date:  2016-09-16       Impact factor: 4.742

Review 2.  Expression of p53 in upper urinary tract urothelial carcinoma.

Authors:  Stephen Mitchell; Erik Mayer; Anup Patel
Journal:  Nat Rev Urol       Date:  2011-08-02       Impact factor: 14.432

Review 3.  Prognostic factors for upper urinary tract urothelial carcinoma.

Authors:  Thomas F Chromecki; Karim Bensalah; Mesut Remzi; Grégory Verhoest; Eugene K Cha; Douglas S Scherr; Giacomo Novara; Pierre I Karakiewicz; Shahrokh F Shariat
Journal:  Nat Rev Urol       Date:  2011-07-05       Impact factor: 14.432

Review 4.  Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: how molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours.

Authors:  David R Yates; James W F Catto
Journal:  World J Urol       Date:  2012-09-18       Impact factor: 4.226

5.  Telomerase detection in the diagnosis and prognosis of cancer.

Authors:  Eiso Hiyama; Keiko Hiyama
Journal:  Cytotechnology       Date:  2004-06       Impact factor: 2.058

6.  Overexpression of human telomerase RNA in Helicobacter pylori-infected human gastric mucosa.

Authors:  K Hur; A F Gazdar; A Rathi; J J Jang; J H Choi; D Y Kim
Journal:  Jpn J Cancer Res       Date:  2000-11

7.  Identification of circulating microRNA signatures for upper tract urothelial carcinoma detection.

Authors:  Jun Tao; Xiao Yang; Pengchao Li; Jifu Wei; Xiaheng Deng; Yidong Cheng; Chao Qin; Xiaobing Ju; Xiaoxin Meng; Jie Li; Min Gu; Qiang Lu; Changjun Yin
Journal:  Mol Med Rep       Date:  2015-08-27       Impact factor: 2.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.